摘要Metabolic dysfunction-associated steatotic liver disease(MASLD)has a high global incidence and associated with increased lipid accumulation in hepatocytes,elevated hepatic enzyme levels,liver fibrosis,and hepatic carcinoma.Despite decades of research and significant advancements,the treatment of MASLD still faces formidable challenges.Nanoprobes for diagnostics and nanomedicine for targeted drug delivery to the liver present promising options for MASLD diagnosis and treatment,enhancing both imaging contrast and bioavailability.Here,we review recent advances in nanotechnology applied to MASLD diagnosis and treatment,specifically focusing on drug delivery systems targeting hepatocytes,hepatic stellate cells,Kupffer cells,and liver sinusoidal endothelial cells.This review aims to provide an overview of nanomedicine's potential in early MASLD diagnosis and therapeutic interventions,addressing related complications.